Arbutus Biopharma Corporation announced that after a distinguished 38-year career, the Company?s co-founder and Chief Scientific Officer, Dr. Michael Sofia, will retire effective December 31, 2024. Dr. Sofia is a globally recognized, Lasker award-winning antiviral drug discovery and development scientist.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.98 USD | +3.11% | +3.47% | +19.20% |
May. 17 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
May. 17 | Sector Update: Health Care Stocks Softer Friday Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.20% | 562M | |
-2.32% | 90.45B | |
+3.68% | 41.45B | |
-10.90% | 33.57B | |
+58.05% | 25.73B | |
-19.56% | 14.73B | |
-9.06% | 12.82B | |
-11.34% | 11.7B | |
-43.53% | 11.44B | |
+3.75% | 8.79B |
- Stock Market
- Equities
- ABUS Stock
- News Arbutus Biopharma Corporation
- Arbutus Biopharma Corporation Announces Retirement of Chief Scientific Officer, Michael J. Sofia Effective December 31, 2024